InSite Vision Incorporated (AMEX: ISV) is focused on developing novel ophthalmic products for the treatment of a growing range of common eye problems, including ocular infection, glaucoma, and retinal disease. Their goal as a company is to provide patients and physicians with better treatment options that help preserve and improve vision worldwide. By leveraging their proprietary DuraSite® drug delivery technology, the company is creating alternative ocular anti-infective therapies that may provide substantial advantages over existing treatment options. For further information, visit the Company’s web site at www.insite.com.
- 17 years ago
QualityStocks
InSite Vision Incorporated (AMEX: ISV)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy
Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee…
-
MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) Pioneers Natural Hydrogen Discovery to Fuel Clean Energy Future
This article has been disseminated on behalf of MAX Power Mining Corp. (CSE: MAXX) (OTC:…
-
Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Positions Itself in Platinum’s Next Chapter
Disseminated on behalf of Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) and may…